Risk Group no RF or RF coded <1 year prior to audit start Testing/Monitoring Denominators Practice population aged >18 Numerator 1 Patient not at risk.

Slides:



Advertisements
Similar presentations
Chronic kidney disease
Advertisements

Chronic kidney disease
CKD ML/LH What are people hoping to cover from the session today?
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Preventing Strokes One at a Time Acute Interventions and Management 2009.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
Hypertension NPN 200 Medical Surgical I. Description of Hypertension Intermittent or sustained elevation in the diastolic or systolic blood pressure:
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
DIABETES AND THE KIDNEYS
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Cardiovascular Hot topics Dr Saqib Mahmud, MRCP(UK)
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
QOF Changes 2015/16 Kate Pilton Development Manager.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Stages of CKD – KDOQI 2002 Definitions
Azara Proprietary & Confidential Controlling High Blood Pressure 2014 Measure Changes Improving Patient Outcomes through Data.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Everything you wanted to know about CKD SUE GILDERSLEVE RENAL NURSE SPECISLIST.
Pharmacological Treatment of Hypertension Update 2012.
CKD: the primary/secondary care interface Daniel Ford Consultant Renal Physician UHCW.
HYPERTENSION NMP. How Common? 25% UK adults 25% UK adults > 50% adults over 60 > 50% adults over 60.
Professor Julia Hippisley-Cox University of Nottingham.
Redwood Community Care Organization Data Capture for ACO Quality Measures.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
Improving the Quality of Physical Health Checks Kate Dale, Mental/Physical Health Lead BDCT.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
Section 5: Configuration of healthcare to manage CKD.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Expert Systems in Renal Disease Kent Renal ServiceUniversity of KentSalford Hospital Chris Farmer Bernhard Klebe Jean IrvingDonal O’Donoghue Paul StevensRoger.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Radka Adlová Arterial hypertension and preventive cardiology.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Project supported by A Package of Innovation for Managing kidney disease in primary care Registered Office: Nene Hall, Lynch Wood Park, Peterborough PE2.
1 Project supported by A Package of Innovation for Managing kidney disease in primary care Registered Office: Nene Hall, Lynch Wood Park, Peterborough.
Renal IT Conference July Widening the Circle of Inclusion Vascular Management in Primary Care Dr. Ian Wilkinson.
CHRONIC KIDNEY DISEASE
NICE CKD Guideline Update Karen Jenkins Consultant Nurse Chair Kent & Medway Renal Collaborative Kent Kidney Care Centre EKHUFT.
NICE Chronic Kidney Disease (CKD) Guidance 2014 Chronic kidney disease in adults: assessment and management (CG182)
Internal Medicine Workshop Series Laos September /October 2009.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Local Enhanced Service Care bundles Dr Andy Kilpatrick, Clinical Lead.
Medicines and CKD Nikki Lawton Medicines Optimisation Pharmacist NMCCG.
Management of Hypertension according to JNC 7
Clinical Management of primary hypertension
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 6: Management in primary care
Hypertension JNC VIII Guidelines.
Nursing Care of Patients with Hypertension
Drugs for Hypertension
The Anglo Scandinavian Cardiac Outcomes Trial
Chronic kidney disease and pre-dialysis
Hypertension: A Risk Factor For Stroke
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Richard Gunn – Project Manager
Volume 93, Issue 4, Pages (April 2018)
Section 5: Configuration of healthcare to manage CKD
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Pharmacological Treatment of Hypertension Update 2012
Internal Medicine Workshop Series Laos September /October 2009
Presentation transcript:

Risk Group no RF or RF coded <1 year prior to audit start Testing/Monitoring Denominators Practice population aged >18 Numerator 1 Patient not at risk Patients who became at risk within last year QOF CKD code or coded renal disease for > 1 year Renal Group No GFR 1 Renal GroupRisk group Risk - not tested GFR 1 >=60 Risk– no CKD3-5 GFR 1 =60 OR No GFR 2 ) Risk– single low GFR GFR 1 and GFR 2 <60 Risk – CKD3-5 unregistered Renal - not tested + GFR 1 : Most recent eGFR within the last 12 months GFR 2 : eGFR prior to GFR 1 where > 3months have elapsed between tests and is reported after 1/1/ * * * = will also be captured in group 2 ** = will also be captured in group 1 or 3 ** Renal - tested ** Numerator 2 lab ACR,/PCR or dipstick proteinuria code in last 12 months Risk - ACR tested + Renal – ACR tested + - Risk – no ACR Renal – no ACR

No GFR 2 OR GFR 2 >=60 Group 1 Coded CKD Denominator Practice CKD QOF register, age >18 Numerator Coded – no CKD 3-5 based on last GFR GFR 1 >= Coded- single GFR - Coded- CKD3-5 GFR 1 : Most recent eGFR within the last 24 months GFR 2 : eGFR prior to GFR 1 where > 3months have elapsed between tests and is reported after 1/1/2008 Practice CKD QOF register Coded – no GFR past 2 year No GFR 1 + -

GFR 1 =60) Group 2 Uncoded with CKD Denominator Practice population aged >18 Numerator on QOF CKD register Patients with registered CKD 3-5 Uncoded patients Uncoded – single low GFR GFR 1 and GFR 2 <60 Uncoded – CKD GFR 1 : Most recent eGFR within the last 24 months GFR 2 : eGFR prior to GFR 1 where > 3months have elapsed between tests and is reported after 1/1/2008

coded with renal disease code coded as CKD stage 1/ 2 on QOF register or uncoded (group1 and 2) Group 3 Early CKD Denominator Practice population aged > CKD captured elsewhere + Early – CKD coded Early – non CKD coded + Numerators

Data extract practicedate of extraction NHS numberpostcode DOBNHS no. ageCan we identify nursing home residents? sexweight/bmi plus date ethnicitysmoking status plus date risk factors (appendix 1)date of risk factor first QOF CKD codedate of first QOF code most recent QOF CKD codedate of recent QOF code renal disease code (appendix 2)date of renal code CKD 1/2 code (appendix 3)date of CKD 1/2 code proteinuria/dipstick code (appendix 4)date of proteinuria code GFR 1 and GFR 2 (N.B. these values are different in the ‘testing’ algorithm from the ‘group’ algorithm date of GFR 1 and GFR 2 creatinine on same dates most recent ACR or PCRdate of ACR/PCR Data extract for all cases (numerators and denominators)

Risk Factors Risk Factors (RFs): Hypertension Diabetes Gout IHD, congestive cardiac failure, atrial fibrillation Cerebrovascular disease Peripheral arterial disease Kidney stones Prostatic hypertrophy Prescription of lithium last 1 year Prescription of tacrolimus or cyclosporin last 1 year Systemic lupus erythamatosis and connective tissue diorders Agreed Exclusions (as to 29/5/13) family history – inadequate data available to GPs NSAIDs – inadequate coding (non-prescription use, prescription but no use) Haematuria – impossible to interpret Conditions with renal involvement which will be under the care of a hospital specialist: sarcoid amyloid myeloma TB

Renal disease codes [This list needs populating from the meeting 29/5/13] Inclusions (agreed 29/5/13): DM with microalbuminuria Systemic disease coded only where nephritis/renal involvement is specified. Alports, Cystic disease, Fabry’s CKD stage 1/2 codes Proteinuria Codes This is both a code for proteinuria (as a renal condition) and codes for dipstick positive proteinuria (>1+). [Sally to update] 467, 4672 to 4675, 4676 to 4678, 467A, 467E, 467H CKD stage 1 without proteinuria Heamaturia codes

GFR 1 >=30 GFR 1 >=15 Staging Denominator Numerator CKD 3b CKD 4 - Coded- CKD3-5 GFR 1 : Most recent eGFR within the last 24 months Confirmed CKD 3-5 CKD 3a GFR 1 >= Uncoded – CKD3-5 Confirmed CKD3-5 = + CKD 5

Monitoring This has now been incorporated into the testing algorithm (first slide). It therefore excludes patients with low GFR but without a QOF code or a renal disease code. [agreed 6 July]

Blood Pressure Collect: Antihypertensive medication classes Angiotensin Converting Enzyme Angiotensin Receptor Blocker Alpha Blocker Beta Blocker Calcium Channel Blocker Diuretic Aldosterone antagonists Other Antihypertensive Contraindication to ACE/ARB Group 1 Coded- CKD3-5 Group 2 Uncoded – CKD3-5 All CKD = + Denominator Last systolic BP Last diastolic BP Non-proteinuric CKD Proteinuric CKD/DM ACR>=30 (PCR>=50), proteinuria code or diabetes code Group 3 CKD1/2 + <=130 systolic and <=80 diastolic + + BP control BP subopt <=130 systolic and <=80 diastolic + BP control BP subopt - - -

Referral ACR>=70 (PCR>=100) and no diabetes in last 12 months All CKD Denominator Taking 4 antihypertensive classes (see previous) and last BP>140/90 in last 12 months eGFR 1 <30 (GFR 2 – GFR 1 ) >5 and GFR 1 is <45ml/min ACR>=30 (PCR>=50) and heamaturia code in last 12 months Referred or reviewed by nephrology/diabet es specialist in last 24 months Referred Coded genetic kidney disease – see renal disease codes GFR 1 : Most recent eGFR within the last 12 months GFR 2 : eGFR prior to GFR 1 where > 3months but <15months have elapsed between tests

CV risk All CKD No code for IHD, CCF, AF, PVD, cerebrovasc disease CV risk - primary collect: statin prescription contraindication to statin prescription exercise advice/weight loss advice stop smoking advice CV risk assessment e.g Q risk, framingham CV primary assessed CV risk - secondary additionally collect: aspirin prescription contraindication to aspirin prescription – eg GI bleeding/ulcer warfarin/clopidogrel prescription

CKD care plan Can only be ascertained by patient reported outcomes

Immunisation 1 Coded- CKD3-5 Uncoded – CKD3-5 Confirmed CKD3-5 = + Influenza immunisation in last 12 months Flu immunised

Immunisation 2 Coded- CKD4-5 Uncoded – CKD4-5 Confirmed CKD4-5 = + Hepatitis B immunisatio n in last 5 years Hep immunised Hepatitis HsAb in last 5 years Hep unknown Hep immune pos unknown neg yes Hep non-immunised n.b. this will depend on local practice – will need survey results to interpret these data

Immunisation 3 Coded- CKD4-5 Uncoded – CKD4-5 Confirmed CKD4-5 = + Pneumococus immunisation in last 5 years Pneumo immunised yes Pneumo non-immunised

Hb monitoring Coded- CKD3b-5 Uncoded – CKD3b-5 Confirmed CKD3b-5 = + Hb sample sent in last 12 months Hb monitored

BMD Coded- CKD4-5 Uncoded – CKD4-5 Confirmed CKD4-5 = + Bone metabolism (Ca/PO4/PTH/vit D level) checked in last 12 months BMD monitored Collect: Vitamin D preparations (long list) alphacalcidol ergocalciferol calcium tablets + variants sevalemer lanthanum aluminium hydroxide calcium acetate ‘dulwich mixture’/magnesium+calcium

The percentage of people with CKD who are assessed for kidney disease progression and related problems according to their disease stage [*, QS6] Based on eGFR/urine laboratory results/timing. For CKD 3B percentage that had Hb measured. The percentage of people with defined indicators for referral who were referred to secondary care [*, QS2] within 3 months of abnormal results eGFR/urine results and timing, high blood pressure despite 4 antihypertensive drug classes, read-codes for referral and/or renal ultrasound, pop-up box for GPs to fill in if phone or advice from specialistswas given The percentage of people with CKD who are assessed for cardiovascular risk [*, QS4] Management The percentage of people with CKD who have a current agreed care plan [QS3] by 1 year read-code on whether patients were informed about their diagnosis (once available), see 4.3. The percentage of people with CKD who have blood pressures in the NICE recommended target range by 1 year [*, QS5] Includes proportion of patients on renin-angiotensin blocking drugs according to proteinuria status The percentage of people with CKD who are treated with statins according to their cardiovascular risk by 1 year [*] Primary and secondary prevention as per updated NICE lipid guideline (once available) The percentage of people with CKD who had their medication reviewed whilst acutely unwell The percentage of people with CKD who were vaccinated for influenza (NICE TA158) For CKD stages 4 &5 this would also apply to pneumococcal virus and Hepatitis B if seronegative (KDIGO CKD guideline 2013). The percentage of people with CKD 4&5 who have phosphate and haemoglobin measurements on GP laboratory systems. [*] #